🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Hikal Limited HIKAL NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.hikal.com
Company Profile ↓
₹210.76
-21.10% 1Y
Mkt Cap₹2,598.69 Cr
P/E-76.92
P/B2.19
Div. Yield0.27%
52W High₹269.09
52W Low₹146.84
Book Value₹97.40
EPS (TTM)₹-2.74

Company Overview

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals industries. The company operates in two segments, Pharmaceuticals and Crop Protection. It provides anti-convulsant, anti-inflammatory, analgesic, anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, anti-viral, and haemorheologic products; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also manufactures pesticides and herbicides, including diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it engages in contract research, custom synthesis, and custom manufacturing of intermediates and active pharmaceutical ingredients. The company operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is based in Navi Mumbai, India.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹1,695.20 Cr (-8.0% YoY); net profit ₹-48.80 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +5.9%, earnings +68.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR -5.4%, profit CAGR -54.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-5.44%
1 Year:5.90%

Compounded Profit Growth

5 Years:-54.09%
1 Year:68.30%

Stock Price Performance

1 Year:-21.10%
6 Months:+16.57%
3 Months:-1.19%
1 Month:-6.76%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 52% of range
₹146.84 ₹269.09
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)44.19 · Neutral
Price Performance
1M-6.76%
3M-1.19%
6M+16.57%
1Y-21.10%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -5.4% CAGR over 5 years.
  • Earnings shrank at -54.1% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-76.92
Industry PE
36.43
Forward P/E
23.42
PEG Ratio
-
Book Value
₹97.40
Price to Book
2.19
P/S
1.52
EV/EBITDA
13.89
Dividend Yield
0.27%

Growth (CAGR)

Revenue 5Y
-5.44%
Profit 5Y
-54.09%
Revenue (YoY)
5.90%
Earnings (YoY)
68.30%

Profitability & Returns

ROCE
-0.96%
ROE
-4.07%
ROA
-2.06%
Profit Margin
-1.95%
Op Margin
-1.41%
Gross Margin
56.34%
EPS (Latest Qtr)
₹1.17
EPS (TTM)
₹-2.74

Balance Sheet & Liquidity

Debt/Equity
0.57
Quick Ratio
0.77
Current Ratio
1.30
Debt
₹683.80 Cr
Total Assets
₹2,365.40 Cr
Current Assets
₹884.10 Cr
Working Capital
₹205.20 Cr

Ownership

Promoter Holding
69.10%
Chg in Prom Hold
0.25%
FII / Inst Holding
6.82%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹2,598.69 Cr
Total Revenue (TTM)
₹1,735.00 Cr
EBITDA
₹236.67 Cr
Free Cash Flow
₹153.90 Cr
Operating Cash Flow
₹302.00 Cr
Shares Outstanding
₹12.33 Cr
Gross Margin
56.34%
Payout Ratio
172.84%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 HIKAL Hikal Limited NSEPHARMA 210.76 -76.92 ₹2,598.69 Cr 0.27% -0.96% -4.07% -5.44% -54.09%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 545.00 Cr388.00 Cr435.00 Cr448.00 Cr514.00 Cr407.00 Cr453.00 Cr-550.00 Cr371.30 Cr316.20 Cr490.70 Cr517.00 Cr
Cost of Revenue --------232.20 Cr186.80 Cr126.30 Cr232.00 Cr216.60 Cr
Gross Profit --------317.80 Cr184.50 Cr189.90 Cr258.70 Cr300.40 Cr
Operating Expenses 457.00 Cr338.00 Cr377.00 Cr383.00 Cr420.00 Cr349.00 Cr378.00 Cr-232.10 Cr198.80 Cr223.90 Cr217.20 Cr237.00 Cr
Operating Income 61.00 Cr22.00 Cr29.00 Cr36.00 Cr62.00 Cr26.00 Cr43.00 Cr-85.70 Cr-14.30 Cr-34.00 Cr41.50 Cr63.40 Cr
EBITDA 88.00 Cr50.00 Cr58.00 Cr65.00 Cr94.00 Cr58.00 Cr75.00 Cr-123.90 Cr26.10 Cr9.10 Cr47.50 Cr64.90 Cr
Interest Expense 13.00 Cr14.00 Cr13.00 Cr14.00 Cr15.00 Cr20.00 Cr19.00 Cr-17.90 Cr17.10 Cr14.90 Cr15.50 Cr14.60 Cr
Pretax Income 49.00 Cr10.00 Cr17.00 Cr22.00 Cr47.00 Cr7.00 Cr25.00 Cr-68.30 Cr-30.40 Cr-47.00 Cr-9.20 Cr8.30 Cr
Tax Provision 12.74 Cr2.90 Cr4.25 Cr5.50 Cr13.16 Cr1.82 Cr6.50 Cr-18.10 Cr-8.00 Cr-12.10 Cr-3.30 Cr-6.10 Cr
Net Income 36.00 Cr7.00 Cr13.00 Cr16.00 Cr34.00 Cr5.00 Cr18.00 Cr-50.20 Cr-22.40 Cr-34.90 Cr-5.90 Cr14.40 Cr
Diluted EPS 2.920.561.021.312.750.411.48-4.07-1.82-2.83-0.481.17

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 872.00 Cr926.00 Cr1,014.00 Cr1,296.00 Cr1,590.00 Cr1,507.00 Cr1,720.00 Cr-2,004.70 Cr1,768.70 Cr1,843.50 Cr1,695.20 Cr
Cost of Revenue --------1,142.27 Cr864.10 Cr837.30 Cr761.70 Cr
Gross Profit --------862.44 Cr904.60 Cr1,006.20 Cr933.50 Cr
Operating Expenses 689.00 Cr745.00 Cr813.00 Cr1,054.00 Cr1,291.00 Cr1,234.00 Cr1,398.00 Cr-713.51 Cr755.00 Cr812.20 Cr876.90 Cr
Operating Income 118.00 Cr114.00 Cr132.00 Cr156.00 Cr205.00 Cr191.00 Cr238.00 Cr-148.93 Cr149.60 Cr194.00 Cr56.60 Cr
EBITDA 182.00 Cr181.00 Cr201.00 Cr242.00 Cr298.00 Cr273.00 Cr323.00 Cr-255.31 Cr266.30 Cr333.40 Cr147.60 Cr
Interest Expense 60.00 Cr62.00 Cr48.00 Cr49.00 Cr58.00 Cr52.00 Cr36.00 Cr-40.93 Cr53.20 Cr75.20 Cr62.10 Cr
Pretax Income 60.00 Cr53.00 Cr80.00 Cr112.00 Cr149.00 Cr127.00 Cr206.00 Cr-105.36 Cr95.50 Cr123.80 Cr-78.30 Cr
Tax Provision 19.20 Cr12.19 Cr12.80 Cr34.72 Cr46.19 Cr41.91 Cr74.16 Cr-26.98 Cr25.90 Cr33.00 Cr-29.50 Cr
Net Income 40.00 Cr41.00 Cr68.00 Cr77.00 Cr103.00 Cr84.00 Cr133.00 Cr-78.38 Cr69.60 Cr90.80 Cr-48.80 Cr
Diluted EPS 3.283.345.496.268.366.8510.8013.026.365.647.36-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 1,292.00 Cr1,275.00 Cr1,379.00 Cr1,542.00 Cr1,686.00 Cr1,768.00 Cr1,913.00 Cr-2,385.48 Cr2,487.10 Cr2,528.90 Cr2,365.40 Cr
Current Assets --------939.02 Cr966.60 Cr995.40 Cr884.10 Cr
Cash & Equivalents --------26.73 Cr12.70 Cr13.00 Cr9.60 Cr
Inventory --------316.74 Cr303.70 Cr334.50 Cr358.10 Cr
Receivables --------441.78 Cr550.30 Cr522.40 Cr441.60 Cr
Total Liabilities --------1,252.01 Cr1,299.40 Cr1,266.60 Cr1,166.60 Cr
Current Liabilities --------661.55 Cr756.60 Cr789.50 Cr678.90 Cr
Long Term Debt --------489.88 Cr422.90 Cr367.20 Cr373.10 Cr
Total Debt 547.00 Cr505.00 Cr598.00 Cr635.00 Cr661.00 Cr646.00 Cr610.00 Cr-748.18 Cr817.60 Cr764.70 Cr683.80 Cr
Total Equity 532.00 Cr563.00 Cr605.00 Cr669.00 Cr757.00 Cr817.00 Cr934.00 Cr-1,133.47 Cr1,187.70 Cr1,262.30 Cr1,198.80 Cr
Shares Outstanding --------12.33 Cr12.33 Cr12.33 Cr12.33 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 102.00 Cr186.00 Cr163.00 Cr139.00 Cr186.00 Cr285.00 Cr229.00 Cr-315.31 Cr186.70 Cr280.40 Cr302.00 Cr
Investing Cash Flow -43.00 Cr-64.00 Cr-102.00 Cr-110.00 Cr-125.00 Cr-164.00 Cr-156.00 Cr--292.34 Cr-173.70 Cr-136.50 Cr-145.30 Cr
Financing Cash Flow -69.00 Cr-124.00 Cr-63.00 Cr-25.00 Cr-55.00 Cr-101.00 Cr-97.00 Cr--7.68 Cr-27.00 Cr-143.60 Cr-160.10 Cr
Capital Expenditure -48.00 Cr-59.00 Cr-105.00 Cr-106.00 Cr-129.00 Cr-158.00 Cr-158.00 Cr--302.62 Cr-204.20 Cr-137.30 Cr-148.10 Cr
Free Cash Flow 54.00 Cr127.00 Cr58.00 Cr33.00 Cr57.00 Cr127.00 Cr71.00 Cr-12.69 Cr-17.50 Cr143.10 Cr153.90 Cr
Net Change in Cash -10.00 Cr-2.00 Cr-2.00 Cr4.00 Cr6.00 Cr20.00 Cr-24.00 Cr-15.29 Cr-14.00 Cr30.00 L-3.40 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------43.0%51.1%54.6%55.1%
Operating Margin % 13.5%12.3%13.0%12.0%12.9%12.7%13.8%-7.4%8.5%10.5%3.3%
Net Margin % 4.6%4.4%6.7%5.9%6.5%5.6%7.7%-3.9%3.9%4.9%-2.9%
ROE % 7.5%7.3%11.2%11.5%13.6%10.3%14.2%-6.9%5.9%7.2%-4.1%
ROCE % --------8.6%8.6%11.2%3.4%

Shareholding Pattern

Insiders
69.10%
Institutions
6.82%
Public Float
22.07%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for HIKAL

Google News Mon, 31 Aug 2026

Don't Race Out To Buy Hikal Limited (NSE:HIKAL) Just Because It's Going Ex-Dividend - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPZ3pvcUgxZkZRUXBvZV8wUUJVb2psT2lIY3ZUakNiTXl1UFFnYmZVVUNRemNjbURTakR0WFNEbnFreG5JbGgyRFBMQXRUZWw5Ti1vQmw0TnF2N2c2Rk1rb0ZSU2N4QUlobXp3NGlud1dNbEFwNE9VZlVrV0lVMmZta0lWT0c5SnFVWGdaRl…

Google News Wed, 22 Jul 2026

Hikal commissions cGMP pilot plant in Pune to strengthen pharmaceutical development - The Economic Times

<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxPenZXWUdZLWR5b0t2WGowdC14MTZfOEU0SDdmcGNQYUZMdTFldTA3SHpmN3IyWV9LTWRjTXRkUmJEOTVnclNHY2psU2Fkamg1X3hqNjduZlAtUzhwMUtoMnByQ1pJV2lZNjFpdGlic2dLbzV3ZkhKNE56eC1tMEwxTTRFZFpTNWxxdHY0MU…

Google News Mon, 06 Jul 2026

Hikal appoints Sandip Parikh as Independent Director - scanx.trade

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPUkFsMHdSYmVTSzZaVEg1dkcyZk5yRGxrYUFUQm9zYldTSzFKU0Zoa09tUmpFTUtzSVZsVnhxb0xLbW1VampyekJpWUdzQWhGZ3A1OS1QUU9vcklRTnRhSWhUUERhVzZXaDU1ZHlZNEh4R0ZQNkdOT203RTNMYjBqbUw2ZnRlczFlNlA0aT…

Google News hu, 06 Aug 2026

Hikal Q1 loss narrows as revenue jumps 31%, margin expands to 9% - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPUnlSLXItTXFHWUpTSEQ5UjFjSTlBcWxHMlRnMmZPbVp0WlNlVlB5anBXckZidl9QeWk5RnNzbEVQQW9kWTZaNmNwTXh1b09QNmdwWnhLZXdBVVNlSHZQQksxbHJ4bFRZVWFTSjM0S3FXOFVCSExkUzdFN2pTT3F1c0ljYkJycVFJZjlUTF…

Google News Wed, 08 Jul 2026

Pharma stocks: Lupin, Torrent hit new peaks; Sun nears summit; here's why - Business Standard

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOWVk0YVdKSGVub1dvbzc1TGRWenlmbWRwNWhNNDRCOGIwZVNkbnNyWmFBX2VQVDdmM2wwTU93b1ROVU5XcFdnaG1Kc0Q1aTJubXFXS3FsUGJDR2xaakhDOG1XVDE2c2lOem5YbThXX2NyNWdvdGZSM2FIMWgtQ2h0b0VzcmUycmhDclhIWE…

Google News Wed, 26 Aug 2026

Hikal Share Price Gains After Sameer Hiremath Named CMD - Univest

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxPWlA3NEFUSkdCbXB4Z3RrNFVKSGJUdzZDYnJhVHFvTkkybkJiemxZNGdjaXF6aXdkT0VzaW9JNjhKcVpHRlc0VzFUazFvWmloQU01N1VqdkNXWFp1cmZoWjNoS2hXTXVlSVo3cHh1SHE1OFZoLS1hckNEdVRIWkw3eQ?oc=5" target="_…

HIKAL — Frequently Asked Questions

What is the current share price of Hikal Limited (HIKAL)?

As of 2026-10-23 04:58 IST, Hikal Limited (HIKAL) trades at ₹210.76 on NSE. Its 52-week range is ₹146.84 to ₹269.09.

What is the market capitalisation of HIKAL?

Hikal Limited (HIKAL) has a market capitalisation of ₹2,598.69 Cr on NSE.

What is the P/E ratio of HIKAL?

HIKAL trades at a trailing price-to-earnings (P/E) ratio of -76.92. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 2.19.

Does HIKAL pay a dividend?

Hikal Limited (HIKAL) currently offers a dividend yield of 0.27%.

What is the return on equity (ROE) of HIKAL?

HIKAL has a return on equity (ROE) of -4.07%. Its return on capital employed (ROCE) is -0.96%.

Is HIKAL a good stock to buy?

This page provides a data-driven analysis of Hikal Limited (HIKAL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space